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Abstract
Cellular  senescence is a state of irreversible cell  cycle arrest.  It  represents an active 
response  of  the  cell  to  various  types  of  intrinsic  and  extrinsic  stresses.  Uncapped 
telomeres, effects of DNA-damaging agents and activation of certain oncogenes belong 
among these stresses. This thesis reviews current models of mechanisms which may 
result in establishment of senescence phenotype. Particular emphasis is being placed on 
a  model of replicative  stress,  a  condition that  leads to  a halt  or  a collapse of DNA 
replication  forks.  Replicative  stress  causes  DNA  damage,  preferentially  in  specific 
regions  of chromosomes,  termed fragile  sites.  DNA damage activates  DNA damage 
response  pathways,  which  are  capable  of  evoking  senescence  phenotype.  Senescent 
cells  with  activated  DNA  damage  response  signaling  have  been  observed  in 
preneoplastic lesions, supporting a current view that cellular senescence plays a role as 
an important tumorigenesis barrier. In the end, adverse effects of cellular senescence are 
briefly discussed including their role in organism aging.
Key words: cellular senescence, replicative stress, fragile sites, DNA damage 
response, telomeres, oncogenes, cancer, aging
Abstrakt
Buněčná  senescence  je  stavem  nevratného  zastavení  buněčného  cyklu.  Představuje 
aktivní odpověď buňky na různé vnější i vnitřní zátěže. Mezi tyto zátěže patří ztráta 
ochranných  konců  telomer,  účinky  DNA  poškozující  agens  a  aktivace  určitých 
onkogenů.  Tato  práce  shrnuje  současné  modely  mechanismů,  které  mohou způsobit 
ustanovení  senescentního  fenotypu.  Zvláštní  pozornost  je  věnována  modelu 
replikativního  stresu,  stavu  vedoucího  k  zastavení  či  kolapsu  replikativní  vidličky. 
Replikativní  stres  způsobuje  poškození  DNA  přednostně  ve  specifických  úsecích 
chromozomů  nazývaných  fragilní  místa.  Poškození  DNA  aktivuje  signální  dráhy 
odpovědi  na  poškození  DNA,  které  jsou  schopné  indukovat  senescentní  fenotyp. 
Senescentní  buňky  s  aktivovanými  drahami  odpovědi  na  poškození  DNA  byly 
pozorovány v preneoplastických lézí. Toto podporuje pohled na buněčnou senescenci, 
jakožto na významnou protinádorovou bariéru. Na závěr jsou krátce zmíněny škodlivé 
účinky buněčná senescence a jejich role ve stárnutí organismů.
Klíčová slova: buněčná senescence, replikativní stress, fragilní místa, odpověď na 
poškození DNA, telomery, onkogeny, rakovina, stárnutí
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53BP1 53-binding protein 1
ActD actinomycin D 
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E2F1 E2F transcription factor 1
EMF electromagnetic fields
ERK extracellular signal-regu-
lated kinases
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Eya1/3 Eyes Absent 1/3
FGF7 fibroblast growth factor 7
FHIT fragile histidine triad gene
FMR1 fragile X mental retarda-
tion 1
FMR2 fragile X mental retarda-
tion 2
FOXO forkhead box O
FS fragiles sites
H2AX H2A histone family,
member X
HDF human diploid fibroblast
HDM2 human double minute 2
HGF hepatocyte growth factor
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CHK1 checkpoint kinase 1
CHK2 checkpoint kinase 2
IFN-β interferon β
IL interleukin
MDC1 mediator of DNA damage 
checkpoint protein 1
MDM2 murine double minute 2
MEK MAP-ERK kinase
MMC mitomycin C
MMP3 matrix metallopeptidase 3
Mre11 meiotic recombination 11
NBS1 Nijmegen breakage syn-
drome 1
NF-κB nuclear factor κ-light-
chain-enhancer of activ-
ated B cells
NF1 neurofibromin 1
OIS oncogene-induced senes-
cence 
p14ARF cyclin-dependent kinase 
inhibitor 2A alternate 
reading frame
p16 cyclin-dependent kinase 
inhibitor 2A
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p21waf1/cip1 cyclin-dependent kinase 
inhibitor 1A
p53 tumor protein p53
PCNA proliferating cell nuclear 
antigen
PIK3 phosphoinositide 3-
kinases
Plk3 polo-like kinase 3
PML promyelocytic leukemia
Pol polymerase
POT1 protection of telomeres 1
PP5 protein phosphatase 5
PTEN phosphatase and tensin 
homolog
RAC1 Ras-related C3 botulinum 
toxin substrate 1
Rb retinoblastoma protein
RFC RAD17-replication factor C
RFC rare fragile sites
RNF186 ring finger protein 186
RNF8 ring finger protein 8
RNR ribonucleotide reductase
ROS reactive oxygen species
RPA replication protein A
S-phase synthesis phase
SA-β-GAL senescence-associated 
β-galactosidase
SASP senescence-associated 
secretory phenotype
SCF SKP1-CUL1-F-box protein
SIPS stress-induced premature 
senescence
SKP1 S-phase kinase-associated 
protein 1
SMURF2 SMAD specific E3 ubiquitin 
protein ligase 2
SSB(s) single-strand breaks
ssDNA single-stranded DNA
STAT5A signal transducer and ac-
tivator of transcription 5A
TERT telomerase reverse tran-
scriptase
TGF-β transforming growth 
factor β
Tlk1/2 tousled-like kinase 1/2
TO53BP1 tumor protein p53 binding 
protein 1
TOPB1 topoisomerase II-binding 
protein 1
TRF1 telomeric repeat-binding 
factor 1
TRF2 telomeric repeat-binding 
factor 2
VEGF vascular endothelial 
growth factor
WWOX WW domain containing 
oxidoreductase
γH2AX phosphorylated H2A his-
tone family, member X
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1. Introduction
Cellular senescence, a state of terminal cell-cycle arrest, was first observed more 
than four decades ago (Hayflick and Moorhead, 1961). Since the time of its discovery a 
view of  cellular  senescence  made  a  dramatic  development.  It  has  been  proved  that 
cellular senescence is not a mere cell culture artifact and that it occurs in vivo as well. 
The hypothesis proposing cellular senescence as a representation of aging on cellular 
level  was  also largely  reconsidered.  Nowadays,  cellular  senescence  is  viewed as  an 
active  response to various  types of intrinsic  and extrinsic  stresses,  such as telomere 
attrition,  effects  of  DNA-damaging  agents  and  activation  of  certain  oncogenes.  In 
common, these stresses are manifested by DNA damage, particularly by the most severe 
DNA double-strand breaks.  DNA double-strand breaks represent  a serious hazard to 
genome integrity. They may result in chromosomal aberrations, potentially leading to 
cancer  development.  Cellular  senescence  prevents  cellular  proliferation  and  thus 
represents  a  tumor-suppressive  mechanism.  The  importance  of  this  mechanism was 
recently  evidenced  in  many  in  vivo studies  (Braig  et  al.,  2005;  Chen  et  al.,  2005; 
Collado et al., 2005; Michaloglou et al., 2005). 
In this work I attempt to  summarize current views on cellular senescence with 
emphasis on the role of replicative stress in this phenomenon.
2. Replicative stress
All  cellular  molecules  have  to  constantly  face  various  endogenous  and 
exogenous stresses. They suffer oxidative stress from reactive oxygen species (ROS) 
generated  in  mitochondrial  respiration,  ionizing  radiation  from  environment  and 
numerous others stressors. Deoxyribonucleic acid (DNA) is no exclusion, due to its role 
as the carrier of genetic information, the damage affecting DNA is even more severe. 
Speaking about DNA integrity, S-phase, in which the DNA replication occurs, 
represents the most vulnerable phase of the cell cycle. DNA is confronted with several 
difficulties intrinsic or pathological to the nature of the replication event, which can be 
broadly termed a replication stress. The term replicative stress was originally coined to 
denote abortion of DNA replication due to the depletion of deoxynucleotide pool. Today 
this term is generally used to refer to any condition that leads to a halt or a collapse of 
DNA replication  forks.  Factors  contributing  to  replicative  stress  are  summarized  in 
Figure 1.
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In addition, otherwise relatively rigid double-stranded DNA structure is during 
replication unwound into single strand regions, which leads to the conversion of single-
strand breaks (SSBs) to more harmful double-strand breaks (DSBs). DSBs represent a 
serious hazard to the structural stability of chromosomes.
Figure 1 | Factors contributing to replicative stress
● Depletion of dNTP pool, caused e.g. by inhibition of ribonucleotide 
reductase (RNR) by hydroxyurea (Krakoff et al., 1968) or folate deficiency 
(Duthie and Hawdon, 1998).
● Inhibition of enzymes involved in DNA synthesis leads to replicative 
stress. DNA polymerases can be inhibited e.g. by aphidicolin (Tedeschi et 
al., 2004); topoisomerases II by etoposide and doxorubicin (Hande, 
1998).
● DNA binding agents, like actinomycin D (Hou et al., 2002) or 
distamycin A (Luck et al., 1977) interfere with replication fork 
progression.
● DNA lesions result in a collapse of fork. 
● Chromosomal fragile sites as specific DNA structures represent 
obstacles for DNA replication and are preferentially prone to induction of 
DNA damage foci (Durkin et al., 2008).
● Hyper-replication triggered by activated oncogenes – potent activator of 
replicative stress, with crucial importance in oncogene-induced 
senescence (Gorgoulis et al., 2005 and Bartkova et al., 2005).
2.1. Fragile sites (FS)
Distribution  of  DNA  lesions  caused  by  replicative  stress  is  not  random. 
Particular  chromosomal  sites,  termed  fragile  sites  (FS),  are  preferentially  prone  to 
induction of DNA damage foci (Magenis et al., 1970; Durkin et al., 2008). In common, 
FS contain repetitive sequences – the CGG triplets repeats or AT-rich repeats (Kremer 
et al.,  1991;  Yu  et al.,  1997).  These repeats  have been observed to form secondary 
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structures,  such  as  hairpins,  which  interfere  with  replication  fork  progression  and 
formation of chromatin structures as well (Gacy et al., 1995; Zlotorynski et al., 2003). 
The  mechanism  of  FS  fragility  is  still  not  fully  elucidated,  effects  of  secondary 
structure-forming repeats are plausible candidates for culprits.
Based of  the  frequency of their  occurrence in  studied population,  FS can be 
divided  into  two  major  groups  –  the  rare  fragile  sites  (RFC),  with  less  than  5% 
incidence in human population and common fragile sites (CFS), which can be found in 
every individual. An extensive summary of known fragile sites can be found in Lukusa 
and Fryns, 2008.
2.1.1. Rare fragile sites (RFC)
RFC can be further classed into folate-sensitive and nonfolate-sensitive groups. 
The latter are specifically promoted by distamycin A or by distamycin A in cooperation 
with  5’-bromo-2’-deoxyuridine  (BrdU).  Folate-induced  RFC  exhibit  CGG-repeats 
(Kremer et al., 1991), whereas folate-independent RFC contain AT-rich repeats (Yu et  
al., 1997). 
Particular RFC belonging to folate-sensitive group have been causally linked to 
certain human disorders. FRAXA site situated in FMR1 gene locus is associated with 
fragile  X syndrome (also  known as  FRAXA syndrome),  which  is  demonstrated  by 
mental retardation (Verkerk  et al., 1991). FRAXE site placed in FMR2 gene locus is 
responsible for milder X-linked non-specific mental retardation (Gu et al., 1996).
2.1.2. Common fragile sites (CFS)
CFS occur in every individual and are highly evolutionarily conserved through 
species. Putting it in perspective with deteriorative effects of CFS breakability, it seems 
to be a bit self-contradictory. It has been suggested that CFS have not been eliminated 
by selection, because they play a specific physiological role. Since CFS are replicated 
very  late  in  S-phase (Le  Beau  et  al.,  1998),  they  may act  as  a  sensing element  of 
completed replication (Durkin and Glover, 2007).
The majority of CFS are specifically induced by aphidicolin (APC; Glover et al., 
1984), the minor and less characterized part by BrdU and 5-azacytidin (Sutherland  et 
al., 1985). APC-induced CFS can be induced also by other factors, like hydroxyurea or 
folate-deficiency, but the treatment with low doses of APC gives the best reproducible 
results.
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2.1.2.1. Role of CFS in cancer
Common fragile sites represent the weak spots of genome integrity. Due to their 
breakability, they are often involved in chromosomal aberrations, which can lead to 
cancer development. 
The best-characterized examples of fragile sites linked to cancer are FRA3B and 
FRA16D. These CFS are situated in loci of tumor-suppressor genes. FRA3B lies in the 
locus of FHIT (Fragile histidine triad) gene. Product of FHIT has been described as the 
target of the protein kinase Src and it presumably plays a role in triggering apoptosis 
(Pekarsky  et  al.,  2004).  FRA16D  occurs  in  the  locus  of  WWOX  (WW  domain-
containing  oxidoreductase)  gene.  Gene  product  of  WWOX interacts  with  p53, 
contributing to induction of apoptosis  (Chang  et al.,  2005).  Deletions that inactivate 
these genes have been detected in numerous cancers,  e.g. in ovarian (Denison  et al., 
2003), pancreatic (Kuroki et al., 2004) and lung tumors (Yendamuri et al., 2003). 
In addition to deletions, CFS are also prone to translocation events, though less 
frequently. For instance, translocations in FRA6E and FRA6F have been observed in 
acute  lymphoblastic  leukemia  and  acute  myeloid  leukemia  (Sinclair  et  al.,  2005). 
Furthermore, CFS can contribute to genome instability by triggering gene amplification 
(Coquelle et al., 1997).
2.1.2.2. Model of instability of CFS (Figure 2)
APC uncouples polymerases from the helicase/topoisomerase complex.  While 
polymerases  are  slowed  down,  helicase/topoisomerase  complex  still  continues  in 
unwinding of dsDNA strand. This results in exhibition of long ssDNA regions (Walter 
et al., 2000). Flexible regions of repetitive sequences can form secondary structures, 
which consequently cause collapse of polymerases (Zlotorynski  et al., 2003). Regions 
of ssDNA also trigger ATR-branch of DNA damage response, which can, among other 
effects, delay cell-cycle progression to provide enough time to complete replication, and 
promotes repair of damaged DNA (see below).
Consistently with this model, depletion of ATR leads to the lack in DDR and 
consequently to increase in DNA lesions associated with CFS. In addition, collapsed 
fork may lead to induction of DSBs which activate ATM-branch of DDR (Ozeri-Galai 
et al., 2008).
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3. The DNA damage response (DDR)
 
Maintenance of genome integrity is crucial for survival at both the cellular and 
organism  level.  Eukaryotic  cells  have  developed  specific  mechanisms  to  deal  with 
genotoxic stresses. The DNA damage response pathways represent important guardians 
of genome stability. 
As mentioned above,  DNA lesions serve as potent  activators  of DDR. DSBs 
activate  the  response  mediated  mainly  by  ATM  kinase,  while  single-strand  DNA 
regions and stalled DNA replication forks trigger ATR kinase. However, it was shown 
that  ATR  can be recruited  also to  DSB damage foci  when ATM activates  nuclease 
activity of meiotic recombination 11 (Mre11), which can generate single-stranded DNA 
regions in DSB foci (Jazayeri et al., 2006).
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Figure 2 | Model for common fragile site instability proposed by 
Durkin and Glover - dsDNA secondary structures, established in ssDNA 
flexible regions of repetitive sequences, interfere with replication fork 
progression, which leads to triggering of DDR (based on diagram from 
Durkin and Glover, 2007).
Figure 3 | The DNA-damage response 
ATM-CHK2 and ATR-CHK1 damage response pathways and their effectors, 
with depiction of known involved proteins. Pathways are discussed in detail 
below. Effectors phosporylated by CHK2 are in red, CHK1 substrates are in 
blue and substrates phosporylated by both kinases are in pink 
(based on diagrams from d'Adda di Fagagna, 2008; Campisi and d'Adda di 
Fagagna, 2007; Bartek and Lukas, 2003).
3.1. ATM-CHK2 branch of DDR
The  DSBs are  recognized  by MRN complex,  composed of  MRE11 (meiotic 
recombination 11), RAD50, NBS1 (Nijmegen breakage syndrome 1) proteins (Nelms et 
al., 1998; Grenon et al., 2001). MRN complex recruits ATM to sites of DNA damage 
(Lee and Paull; 2004). Consequently, ATM forms homodimers and is activated through 
intramolecular phosporylation on serine residues 1981 (Bakkenist and Kastan, 2003). 
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Recently  it  was  demonstrated  that  ATM  activation  is  inevitably  preceded  by  its 
phosphorylation on serine 794 by cyclin-dependent kinase 5 (Cdk5; Tian et. al., 2009).
Alternatively,  based  on  the  observation  that  even  a  few  DSBs  can  rapidly 
activate a large amount of ATM, Bakkenist  and Kastan (2003) suggested that  ATM 
activation  is  not  stimulated  via  binding  to  DSBs  foci.  They  proposed  that  ATM 
initiating  stimulus  may  be  sparked  by  alteration  of  chromatin  structure,  which 
accompanies  the  DBSs.  However,  the  exact  mechanism  by  which  the  chromatin 
alteration might cause initial activation of ATM has not been clarified. 
The role of protein phosphatase 5 (PP5) is essential in ATM activation, as its 
deficiency results in the lack of ATM-mediated cell cycle arrest (Ali et al., 2004; Yong 
et al., 2007). Nevertheless, its direct effect on ATM remains unknown. Speculatively, in 
response to DSBs, PP5 may remove putative inhibitory phosphates from ATM and thus 
provide its activation (Ali et al., 2004).
Once activated, ATM dimers dissociate into monomers  (Bakkenist and Kastan, 
2003)  which consequentially phosphorylate histone H2AX on serine 139. H2AX can 
undergo this phosporylation only if it has been earlier dephosphorylated on tyrosine 142 
by  Eya1/3  phosphatases  (Cook  et  al.,  2009). H2AX  phosporylated  on  serine  139 
(γH2AX)  binds  MDC1,  mediator  of  DNA  damage  checkpoint  protein  1.  MDC1 
interacts  with  NBS1, which leads to the  increase of MRN  complex  concentration at 
DSBs foci (Melander et al., 2008). MRN complexes in turn recruit more ATM, which 
successively phosphorylates more H2AX. Thus a positive feedback loop is set up. 
MDC1 also promotes accumulation of RNF8 ubiquitin ligase at DSBs. RNF8 
ubiquitinates histones H2A and γH2AX. (Mailand et al., 2007). Ubiquitinated histones 
H2A  attract  other ubiquitin  ligase,  RNF186  that  further  increases  histone 
ubiquitinylation.  In  this  way  modified  DSBs-flanking chromatin  then  serves  as  a 
landing platform for downstream DDR mediators, such as  tumor protein p53 binding 
protein  1  (53BP1;  Doil  et  al.,  2009).  53BP1 promotes  ATM activity  in  a  pathway 
parallel to MDC1-NBS1 pathway. It is suggested that when one of these amplification 
supporting pathways is set up, the other is inhibited as redundant (Mochan et al., 2003).
While  the activity of ATM reaches a certain level, it  activates CHK2 kinase. 
Notably, ATM can in a minor manner also activate activate CHK1 (Gatei et al., 2003). 
3.2. ATR-CHK1 branch of DDR
The ATR branch of DDR consists of different proteins than ATM branch, but in 
the structure of signal transmission these pathways share many similarities (Figure 3). 
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Firstly, the ssDNA region is coated by replication protein A (RPA), which recruits the 
ATRIP-ATR complex (Cortez et al., 2001; Zou and Elledge et al., 2003). ATRIP role in 
ATR localization to DNA damage foci via its interaction with ssDNA-RPA complex 
has been believed to be crucial.  Interestingly, a splice variant of ATRIP, which is not 
able to bind to ssDNA-RPA complex, still supports the ATR activation, implying that 
binding to RPA–ssDNA is not absolutely required for ATRIP-ATR function (Ball et al., 
2005).
ATR activity  is  promoted by the  PCNA-related  9-1-1 complex,  consisting of 
RAD9, RAD1, HUS1.  9-1-1 complex is loaded to DNA damage foci by clamp loader 
RAD17-RFC complex (RAD17-replication factor C) (Zou  et al., 2002). Additionally, 
ATR activity  can  be  promoted  also  by  topoisomerase  II-binding  protein  1,  TOPB1 
(Kumagai  et al.,  2006) In contrast to ATM, ATR does not undergo phosphorylation 
during its activation.  Boosted ATR then in cooperation with phosphorylated  adaptor 
protein claspin phosphorylates and thus activates CHK1 (Kumagai et al., 2000). 
3.3. CHK1 and CHK2 kinases and down-stream signal transduction
Diffusible kinases CHK2 and CHK2 spread the signal through the nucleus to its 
effectors, Figure 3 (Lukas et al., 2003; Bekker-Jensen et al., 2006). For delay or arrest 
of  cell-cycle,  CDC25  phosphatases,  p53  and  its  negative  regulator  HDM2  (and 
CDC25A in case of S-checkpoints) are particularly important. 
Phosphorylated  CDC25  phosphatases are marked by SCF (SKP1-CUL1-F-box 
protein)  ubiquitin  ligase and consequently  dispatched by proteolysis.  Since  they  are 
necessary for activation of cyclin dependent kinases (CDKs), their dispatch promptly 
results in cell-cycle delay (Mailand et al., 2000; extensively reviewed by Donzelli and 
Draetta, 2003). 
Activation of p53 via its phosporylation  (mediated by ATM, ATR, CHK1 and 
CHK2)  and additional  down-regulation  of  its  inhibitor  HDM2 leads  to  transcription 
activation of p21waf1/cip1  gene (p21). The p21 acts as CDK inhibitor and thus contributes 
to cell-cycle delay (see below).
As  shown  before,  the  CHK1  and  CHK2  share  many  substrates  (Figure  3). 
Nevertheless,  their  roles  are  not  mutually  interchangeable.  CHK1  regulates  the 
physiological  level  of  CDC25A,  balancing  its  pro-replicative  activity.  Its  effect 
represents  a  "housekeeping" mechanism,  which  is  essential  to  maintain  unperturbed 
replication (Sorensen et al., 2003). CHK2 conditionally amplifies the rate of CDC25A 
degradation in response to DSBs and thus causes S-phase delay (Bartek and Lukas, 
14
2003). Different importance of these kinases is well reflected by mice knockout models. 
CHK1-deficiency leads to embryonic lethality due to p53-independent apoptosis (Liu et  
al., 2000). On the contrary, CHK2-deficient mice are viable and do not exhibit extensive 
development of tumors, unless they are exposed to  carcinogenic agents (Hirao  et al., 
2002). 
If the DNA lesions are correctly repaired, DDR is then shut down by remodeling 
of  chromatin  structure.  The  molecular  mechanism  of  this  action  remains  to  be 
elucidated. However, when the DNA damage is excessively severe to be repaired during 
transient cell cycle arrest, persistent DDR can trigger permanent cell cycle arrest termed 
cellular senescence.
4. Cellular senescence
The  cellular  senescence  is  a  state  of  irreversible  cell  cycle  arrest.  This 
phenomenon was first described by Hayflick and Moorhead (1961). They observed that 
in vitro cultured human diploid cells can undergo only a limited number of doublings. 
The proliferative limit (Hayflick limit) was determined at 50±10 cumulative doublings 
for human diploid fibroblast in culture (Hayflick and Moorhead 1961). Hayflick (1965) 
also proposed a hypothesis that limited proliferating capability may be a representation 
of  aging on cellular  level.  However,  cellular  senescence should not  be viewed as  a 
physical  state  of  the  cell  as  it  chronologically  grows old.  It  is  caused  by an active 
response of cell to various stressors, as described below.
4.1. Characterization of senescent cells
Senescent  cells  exhibit  various  characteristic  changes  at  all  levels  from gene 
expression to morphology. Their cytoplasm increases in volume and flattens (Figure 3; 
Bayreuther et al., 1988). 
The  expression  of  many  genes  throughout  senescence  is  altered  (extensive 
comparison of gene expression in various types of senescence was published by Pascal 
et al., 2005). In particular, overexpression of cell cycle inhibitors – cyclin dependent 
kinases (CDKs) inhibitors p21 (Shelton et al 1999) and p16INK4a (p16; Hara et al., 1996) 
is causal for cell cycle arrest. These CDKs inhibitors are key components of pathways 
that establish and maintain cell cycle arrest (see below; Sherr et al., 2002; Campisi and 
d'Adda di Fagagna, 2007). Interestingly, senescent cells upregulate either p21 or p16. 
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Figure 4 | Mitotic and postmitotic fibroblast morphotypes (×86)
Morphotypes of human diploid fibroblasts (HDF) during their ontogenesis, as 
described by Bayreuther and colleagues: (A) Mitotic (HDF) cell-type F I.; 
Mitotic HDF cell-type F II. (B); Mitotic HDF cell-type F III. (C); Postmitotic 
HDF cell-type F IV. (D); Postmitotic HDF cell-type F IV. (E); Postmitotic HDF 
cell-type F IV. (F); Postmitotic degenerating HDF cell-type F IV. (G). (C) and 
(D) well illustrate morphological changes of senescent cells.
Figure from Bayreuther et al., 1988
Relationship between the regulation of expression of these two CDKs inhibitors is not 
fully  elucidated.  Presumably,  some  stimuli  induce  expression  of  p21,  while  others 
upregulate p16 (Herbig et al., 2004). 
Then again, Stein and colleagues (1999) demonstrated the different dynamics of 
p21  and  p16  accumulation.  Early  increased  levels  of  p21  exhibit  a  decrease  after 
senescence is achieved. This is followed by a rise of p16 levels, suggesting that p16 
overexpression  may  be  crucial  for  stable  maintenance  of  senescence.  Another 
overexpressed  protein  that  seems  to  have  growth  suppressive  function  is  cyclin  D2 
(Meyyappan et al., 1998; Shelton et al., 1999).
In  contrast,  the  proteins  that  stimulate  cell  proliferation  are  repressed.  This 
repression  is  often  facilitated  by  hypophosphorylated  retinoblastoma  protein  (Rb), 
which inactivates transcription factor E2F (Hiebert et al., 1992; Narita et al., 2003). 
However, not all changes in gene expression are linked directly to growth arrest. 
In addition senescent cells overexpress genes, whose secreted products can change the 
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tissue  microenvironment:  degradation  enzymes  –  e.g.  matrix  metallopeptidase 3 
(MMP3; Parrinello  et al., 2005), growth factors – vascular endothelial growth factor, 
(VEGF; Coppe,  at  al.,  2006),  fibroblast  growth factor  7 (FGF7),  hepatocyte  growth 
factor (HGF), amphiregulin (AREG; Bavik at al., 2006) and several cytokines such as 
IL-1, IL-6, IL-8, IL-11 etc. (Coppe et al., 2008). The findings of Krtolica and colleagues 
(2001) also suggest that this senescence-associated secretory phenotype (SASP) might 
paradoxically  stimulate  tumorigenesis  of  neighboring  cells.  They  observed  that 
senescent fibroblast can via SAPS stimulate preneoplastic and neoplastic epithelial cell 
proliferation,  while  normal  epithelial  cells  do  not  respond  to  SAPS  by 
hyperproliferation. These effects of SAPS dispute with the tumor-suppressive role of 
cellular senescence. Possible explanation of this contravention is proposed by the theory 
of antagonistic  pleiotropy (see chapter  4.4.1.).  Disruption of tissue homeostasis  may 
likewise contribute to age-related pathologies (Campisi  et al., 2005). Moreover, recent 
studies reveal that secreted cytokines IL6 and IL8 can together with their receptors and 
transcription  factors  (e.g.  NF-κB,  C/EBPβ)  form  positive-feedback  loops,  which 
promote the establishment  of senescence (Acosta  et al.,  2008, Kuilman  et al.  2008; 
Bartek et al., 2008).
Senescent cells frequently acquire resistance to certain apoptotic stimuli (Wang 
et al., 1995; Seluanov et al., 2001). The apoptotic resistance might partially explain why 
senescent  cells  accumulate  in  tissues  with  age.  Nevertheless,  the  persistence  of 
senescent  cells  in  tissues  may  vary,  depending  on  their  cellular  type.  For  example, 
senescent  melanocytes  from  pigment  naevi  can  continue  in  existence  for  years 
(Michaloglou  et al., 2005). On the other hand, the senescent cells of liver carcinomas 
are promptly dispatched by phagocytes (Xue et al., 2007).
Until  now,  there  are  no  markers  exclusively  specific  for  senescent  cells. 
Presently,  as  a  common  but  not  universal  senescence  biomarker  in  vitro serves 
senescence-associated β-galactosidase activity (SA-β-GAL), detectable at pH 6 (Dimri 
et  al.,  1995).  However,  it  reflects  the  enhanced  activity  of  acidic  lysosomal 
β-galactosidase  (EC  3.2.1.23)  at  suboptimal  pH,  being  detectable  due  to  increased 
lysosomal  mass  in  senescent  cells.  This  activity  is  not  directly  involved  in  the 
development  of  senescence  phenotype  (Kurz  et  al.,  2000;  Lee  et  al.,  2006). 
β-galactosidase activity can be also induced by  serum starvation and cell confluence. 
Yet, in these cases  β-galactosidase activity can be reversed by  re-culturing of cells in 
sufficient conditions, whereas SA-β-GAL activity cannot be reversed in this way (Yang 
and Hu, 2005).
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4.2. Molecular pathways establishing senescence
Senescence is established and maintained by p53 and pRb pathways (Figure 5). 
Despite  the possible  interactions  between these  pathways,  they are  able  to  establish 
senescent  growth  arrest  independently  of  each  other.  Activation  of  the  particular 
pathway  depends  on  primary  stimuli  and  cell  type.  Yet  an  understanding  why one 
pathway is chosen over the other is in many cases still incomplete.
Figure 5 | p53 and pRb pathways 
Molecular pathways establishing senescence. Growth-arrest promoting 
effectors are in red. Pro-proliferative effectors are in blue.
4.2.1. The p53 pathway
The p53 pathway can be activated by DNA damage response or by oncogene 
signaling.  DDR  kinases  CHK1  and  CHK2  activate  p53  directly  trough  its 
phosphorylation  and  inhibition  of  its  negative  regulator  Hdm2,  homologue  Mdm2 
(mouse double minute 2) in mice. Oncogene signaling induces alternative reading frame 
protein p14ARF (alternatively called p14, ARF, and p19ARF in mice; oncogene-induced 
pathways demonstrated in figure 9, page 29) encoded at INK4 gene locus together with 
p16 (Stott et al., 1998). Then p14ARF binds and blocks Hdm2 action (Chang et al., 2007). 
In addition, p14ARF transcription can be promoted by E2F. This represents one of the 
cross-talks between p53 and Rb pathways (Bates et al., 1998).
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Hdm2 is an E3 ubiquitin ligase, which directly interacts with p53 and facilitates 
its degradation (Kubbutat  et al., 1997).  This regulation has the character of a negative 
feedback loop, since increased activity of p53 results in increased production of Mdm2 
(Lahav et al., 2004).
Active transcription factor p53 triggers transcription of p21 inhibitor of cyclin 
dependent  kinases  (Brown  et  al.,  1997).  Inhibition  of  CDKs  (CDK4/6)  results  in 
hypophosphorylation  of  Rb,  which  can  then  suppress  pro-proliferative  transcription 
factor E2F. These actions lead to cell-cycle delay or arrest. An experimental inactivation 
of p53 is able to reverse p53-mediated growth arrest (Beausejour et al., 2003).
4.2.2. The Rb pathway
 Initiation  of  Rb  pathway  comes  usually  second  to  p53  pathway  (Stein  et 
al.,1999).  Interestingly,  locus  INK4 encodes p14ARF (p14-INK4b) and also p16 (also 
known as INK4a) (Stott et al., 1998). Expression of p16 can be stimulated by oncogenes 
via activation of Ets transcription factors (Figure 9). Yet, it remains unclear how other 
stimuli can induce activation of the Rb pathway. The p16 acts as potent CDK inhibitor, 
keeping Rb in active hypophosphorylated form (Alcorta et al., 1996).
The  Rb  can  repress  E2F  through  formation  of  Rb-E2F  complex,  which  is 
predominantly transcription repressive (Hiebert et. al., 1992). In addition, Rb promotes 
establishment  of  senescence-associated  heterochromatin  foci  (SAFS)  which  provide 
stable repression of E2F target genes. Once established, SAPS no longer need activated 
Rb  pathway (Narita  et  al.,  2003).  This  is  consistent  with  the  observations  that  Rb 
mediated arrest cannot be reversed, as opposed to p53 mediated one (Beausejour et al., 
2003).
4.3. Stimuli that induce cellular senescence
4.3.1. Replicative senescence - telomere-dependent senescence
The vertebrate telomeres are complexes of repetitive noncoding DNA sequences 
(5´ – (TTAGGG)n – 3´)  (Moyzis  et al., 1988) and associated proteins at the ends of 
linear  chromosomes.  They  are  terminated  at  protruding  3´  single-stranded  DNA 
(sometimes referred to as G-overhang) that  together with binding proteins forms the 
characteristic loop (Griffith  et al., 1999;  Grandin and Charbonneau, 2008; De Boeck 
et al.,  2009) (Figure  6).  These  nucleoprotein  structures  serve  as  a  protective  cap, 
preventing chromosomal fusions (McClintock, 1941).
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Figure 6 | Structure of vertebrate telomere 
with depiction of main binding proteins – telomeric repeat-binding factor 2 
(TRF2); telomeric repeat-binding factor 1 (TRF1), which directly bind 
double-stranded telomeric DNA; protection of telomeres 1 (POT1) binds to 
single-strand 3´extension and probably plays a role in formation of D-loop. 
These proteins together with other telomere binding proteins hold the 
telomere structure. Whole protein complex is also named shelterin or 
telosome.
Figure based on articles and accompanying diagrams of Grandin N., 
Charbonneau M. 2008; De Boeck, G. et al., 2009.
According to the Olovnikov's hypothesis (1971), the 5´ end of newly synthesized 
strand meets the "end replication problem" (Olovnikov, 1996) as there is no place for 
Okazaki fragment at a tip of the linear strand. This problem is overcame by the activity 
of  specific  enzyme,  ribonucleoprotein  telomerase  reverse  transcriptase  (TERT), 
featuring the ability of 5´ → 3´ DNA synthesis, dependent on TERT own RNA template 
(Greider and Blackburn, 1987). The TERT is active in early development, but later on 
most cells lose an ability to express the TERT constitutionally or they express it at a 
very  low level  (Collins  and Mitchell,  2002).  This  results  in  attrition  of  the  ends  of 
telomeres  with  every  cell  division  (Olovnikov,  1996;  Harley  et  al., 1990).  The 
homogeneous  telomere  shortening  has  been  proposed  as  an  intrinsic  counting 
mechanism for the potential of cellular division. Finally, when telomeres reach critical 
length, they induce replicative senescence (Olovnikov, 1996). 
More  recently  it  was  demonstrated  that  telomere  shortening  is  not  a  strictly 
autonomous  clock-like  mechanism and that  it  can be  also affected  by physiological 
stress.  The cells  exposed to  high oxygen conditions  show more rapid shortening of 
telomeres than those which were exposed to lowered oxygen tension (von Zglinicki et 
al.,  1995;  Forsyth  et  al.,  2003).  The average  length  of  telomeres  in  senescent  cells 
ranges between 5 and 7.6 kbp (Allsopp and Harley, 1995). By contrast,  the original 
length in "young" cells varies from 10 to 15 kbp (Lansdorp, 1995). 
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Figure 7 | The model of the end-replication problem
A -  The end of  newly  synthesized 5´strand  cannot  be  completed in  full 
length as there is no place for Okazaki fragment at tip of the 3´ strand. 
(based on Shay and Wright, 2000)
B – TERT overcoming end-replication problem via prolongation of 
3´strand
In addition,  it  has been proposed that it  is  not the average length of cellular 
telomeres that triggers senescence program, but the length of the shortest ones (Hemann 
et al., 2001; Zou et al., 2004). The decisive length of shortest telomeres was suggested 
to be 2 kbp or even less (Martens et al., 2000).
Based on the observation that telomere length not always stringently correlates 
with the establishment of senescence, another hypothesis has raised. It suggests that the 
determining feature is the structure of telomere, not its exact length. As shown in Figure 
6, 3´overhang forms a particular protective cap. It seems that telomeres lose this cap at 
senescence  due to  the  erosion  of  3´overhang (Stewart  et  al.,  2003;  Ben-Porath  and 
Weinberg,  2004).  Together  with  the  loss  of  the  overhang,  there  is  also  a  loss  of 
telomeric  proteins,  most  notably  the  TRF2 and POT1,  which  inhibit  the  activity  of 
checkpoint kinases ATM and ATR (Karlseder  et al., 2004; Denchi  et al.,2007). This 
results  in  exposure  of  chromosomal  ends,  which  are  recognized  by  DNA  repair 
machinery as double strand breaks, triggering DNA damage response and permanent 
activation of cell  cycle  checkpoints  evolving into cellular  senescence (Herbig  et al., 
2004).
Telomeric  structure  can  also  be  disrupted  artificially  by  overexpression  of a 
dominant negative TRF2 mutant or by G-rich telomeric oligonucleotides (Saretzki  et  
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al.,  1999). In both cases,  disturbed telomeres  lead to premature induced senescence, 
which supports the principal role of protective telomeric structure.
According to this view, the role of TERT should be also reconsidered. Its key 
effect  is  not  extension  of  the  whole  telomere,  but  rather  elongation  of  3´overhang 
(Masutomi et al., 2003).
4.3.2. Stress-induced premature senescence (SIPS)
An irreversible cell  cycle arrest prior  to reaching Hayflick limit,  triggered by 
various sub-lethal stresses, is referred to as stress-induced premature senescence (SIPS) 
(Toussaint  et  al.,  2000).  SIPS  can  be  induced  by  excessive  attrition  of  telomeric 
structure due to oxidative stress or other factors, as mentioned before. Notably, it can be 
activated  also  in  telomere  independent  manner  through  nonspecific  DNA  damage 
(Gorbunova et al., 2002). In fact, the process of SIPS is established by the same DNA 
damage response pathways like in the case of replicative senescence. 
Prematurely  senescent  cells  display  very  similar  phenotype  to  those  which 
senesce replicatively. Nevertheless, it  has been shown that they differ at the level of 
protein  expression.  The  differences  exhibited  by  cells  undergoing  SIPS  have  been 
linked to effects of subcytotoxic stress and termed “molecular scars” (Brack et al., 2000; 
Dierick et al., 2002; Pascal et al., 2005).
Activating  agent  of  SIPS  can  be  practically  any  stressor  causing  directly  or 
indirectly  DNA damage.  Oxidative  stress  is  likely  the most  common one.  Oxidized 
base, like 8-oxodeoxyguanine, can result in transversion (G-C → T-A) and can be used 
as  oxidative  stress  marker,  as  well.  However,  oxidations  of  the  sugar-phosphate 
backbone are more significant for SIPS, as they can lead to DNA double strand breaks 
and hence to DNA damage response. Notably, agents which do not activate senescence 
via oxidative stress, often act through induction of common fragile sites and replicative 
stress.  Numerous  stressors,  known  for  triggering  SIPS, are  summarized  in  Table 1 
(based on Toussaint et al., 2002), including a mechanism of their DNA damage effect. 
As the process of SIPS can be telomere independent, it can affect both normal 
cells and cancerous cells, expressing TERT (Kim et al., 1994). The induction of SIPS is 
indeed  one  of  the  effects  of  anticancer  treatments,  like  radiotherapy  (Suzuki  and 
Boothman,  2008) or chemotherapy (various anti-cancer  drugs mentioned in Table 1, 
marked  with  “+”,  according  to  the  list  of  approved  drugs  by  U.S.  Food and  Drug 
Administration;  FDA).  Originally  it  has  been  thought  that  the  main  effect  of  these 
therapies  is  to  cause  cell  death  via  apoptosis  or  mitotic  catastrophe,  but  lately  was 
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shown that nonlethal SIPS plays also important role (Schmitt  et al., 2002; Roninson, 
2003; Schmitt, 2007; Suzuki and Boothman, 2008). Senescence induced in normal cells 
is also plausibly responsible for some of side-effects of these treatments.
Table 1 | The stressors causing SIPS
stressor damage mechanism
5-Bromo-2′-deoxyuridine (BrdU)
(Michishita et al., 1999)
A thymidine analogue, which incorporates into the 
DNA during its synthesis and alters its structure, 
making it more sensitive to secondary stressors, 
therefore increasing danger of sister–chromatid 
exchanges, mutations and strand breaks 
(Taupin, 2007).
Actinomycin D (ActD)
(Robles and Adami, 1998)
+
ActD binds directly to DNA in the d(CpG) sequences, 
hence it interferes with replication as well as with 
transcription (Hou et al., 2002).
Aphidicolin (APC)
(Yogev et al., 2006)
Specific inhibitor of DNA polymerases α and δ, 
capable of induction of common fragile sites 
(Tedeschi et al., 2004).
Bleomycin (BLM)
(Robles and Adami, 1998)
+
The main active component, bleomycin A2, binds to 
DNA, which results in a DNA-bleomycin-Fe2+-O2 
complex; later reduction of oxygen leads to reactive 
oxygen species (ROS), which cause deletions and 
strand breaks (Ackland at al., 1988).
Cis-platin (cisplatinum; cis-
diamminedichloridoplatinum(II); CDDP)
(Wang et al., 1998)
+
The DNA crosslinker specific for guanine or guanine/
adenine residues in the sequences d(GpG), d(ApG),
less frequently than between d(GpNpG) and 
d(ApNpG), and between deoxyguanosines in 
opposite strands. The DNA crosslinks block 
replication, thus indirectly inducing strand breaks 
(Bernges and Holler, 1991).
Deficiency in glucose-6-phosphate 
dehydrogenase (G6PD)
(Ho et al., 2000)
G6PD is necessary for generation of reduced 
nicotinamide adenine dinucleotide phosphate 
(NADPH). NADPH maintains the level of glutathione, 
which causes detoxification of free radicals. 
Deficiency in G6PD therefore indirectly results in 
increased oxidative stress (Ho et al., 2000).
Distamycin A (DM)
(Suzuki et al., 2002)
DM alters DNA conformation by interaction with AT 
base pairs in the minor groove of DNA, acts 
synergistically with BrdU (Luck et al., 1977).
Ethanol (EtOH)
(Dumont et al., 2002)
EtOH modifies membranes fluidity, which results in 
destabilisation of cellular homeostasis, also 
contributing to oxidative stress (Dierick et al., 
2002).
Etoposide 
Doxorubicin (adriamycin) 
(Robles et al., 1999)
+
The topoisomerase II inhibitors, capable of inducing 
of DNA strand breaks. 
In addition, doxorubicin can induce free-radical 
formation, thus contributing to oxidative stress.
(Hande, 1998)
Homocysteine
(Xu, Neville and Finkel, 2000)
Various cytotoxic properties (reviewed by Perna et 
al., 2003), including formation of H2O2 through 
protein binding and causing oxidative stress.
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Table 1 | The stressors causing SIPS
stressor damage mechanism
Hydrogen peroxide (H2O2) 
(Frippiat et al., 2001)
H2O2 react in Fenton reaction to yield hydroxyl 
radical [·OH]:
H2O2 + Fe2+ → Fe3+ + [·OH] + OH-
Extremely reactive [·OH] causes most of oxidative 
stress (Henle and Linn, 1997)
H2O2 indirectly induces higher order chromatin 
degradation (enzymatic excision of chromatin loops 
and their oligomers in matrix-attachment regions) 
(Konat, 2003)
Hydroxyurea (HU)
(Yeo et al., 2000)
+
The inhibitor of ribonucleotide reductase (RNR). The 
inhibition of RNR results in a lack of the 
deoxynucleotides required for DNA synthesis and 
accordingly leads to DNA single strand breaks 
(SSBs) (Krakoff et al., 1968).
Hyperoxia
(von Zglinicki et al., 1995)
O2 giving rise to superoxide O2− and other reactive 
oxygen species (ROS); causing oxidative stress; 
moreover O2−. dismutases can produce H2O2 and can 
also reduce and release Fe3+ from ferritin, both 
contributing to genesis of [·OH] (Henle and Linn, 
1997).
Mitomycin C (MMC)
(Yang and Hornsby, 1989)
+
The DNA crosslinker exceedingly specific for guanine 
residue in the d(CpG) sequences (Tomasz, 1995).
Phleomycin D1
(Robles et al., 1999)
The bleomycin analogue, causes DSBs and SSBs 
through the production of free oxygen radicals
(Robles et al., 1999)
Radiofrequency radiation (RFR) 
electromagnetic fields (EMF)
(Rodemann et al., 1989)
The mechanism by which RFR EMF cause DNA 
damage remains currently unknown. However, the 
energy level of RFR EMF is not sufficient to cause 
direct breakage of chemical bonds, thus the effects 
are probably indirect through production of free 
radicals.
Notably, not all papers observe DNA damage as a 
consequence of RFR EMF (Phillips et al., 2009).
Tert-butylhydroperoxide (t-BHP)
(Dumont et al., 2000)
A direct-acting oxidative stress-inducing agent 
(Adams et al., 1993).
Ultraviolet light A (UVA)
(400–320 nm)
(Wlaschek et al., 2000)
Ionizing radiation - damage DNA by its direct 
ionization (capability of bond breakage) or indirectly 
via production free radicals (major contribution).
Yet the DNA bases absorb weakly above 320 nm, 
UVA can still produce at least some cyclobutane 
pyrimidine dimers (CPDs) directly (Jiang et al., 
2009).
Ultraviolet light B (UVB) 
(320–280 nm)
(Medrano et al., 1995; Chainiaux et al., 2002)
Ionizing radiation.
Furthermore, UVB produces cyclobutane pyrimidine 
dimers (CPDs) at TT and TC sites, with low 
abundance also in CC and CT sites. Nevertheless, 
CC sites CPDs, even generated at low quantities, 
show high mutagenic potential (Cadet et al., 2005).
X-rays
(Suzuki and Boothman, 2008)
Ionizing radiation.
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Table 1 | The stressors causing SIPS
stressor damage mechanism
γ-rays 
(Igarashi et al., 2007)
Ionizing radiation.
4.3.3. Oncogene-induced senescence (OIS)
An activation of certain oncogenes also belongs among stresses which can lead 
to senescent phenotype. Oncogenes are traditionally connected with cell transformation 
and cancer. Nevertheless, in normal cells the sole activation of oncogene does not end in 
cellular transformation. On the contrary, the initial burst of proliferation is succeeded by 
proliferative  arrest.  This  fact  was first  observed on  cultured fibroblasts,  which were 
transduced  with  activated  RAS allele  H-RASV12 (Serrano  et  al.,  1997).  Later  on, 
oncogene-induced  senescence  (OIS)  was  described  for  numerous  other  oncogenes 
(summarized in Table 2). Not surprisingly, many of them represent RAS effectors in 
signaling  pathways  transducing  mitogenic  and  surviving  signals  (e.g.  Raf/MEK/Erk 
pathway; Akt/PKB pathway; Figure 9).
OIS  occurrence  in  vivo has  been  questioned  for  a  long  time.  Opponents 
demonstrated  that  in  in  vitro studies,  oncogenes  have been expressed  ectopically  in 
supraphysiological  levels.  On  the  contrary,  murine  embryonic  fibroblasts which 
expressed  a  single  activated  K-RASV12 allele  driven  by  its  own  promoter,  did  not 
establish senescence phenotype and proliferate like immortal cells (Guerra et al. 2003). 
These findings led to the hypothesis that OIS is an exclusively artificial phenomenon 
caused  by  overexpression  of  oncogenes.  Nonetheless,  later  studies  presented  clear 
evidence that OIS occurs in vivo as well. OIS presence has been independently detected 
in lung adenomas (Collado et al., 2005), T-cell lymphomas (Braig et al., 2005), prostate 
tumors (Chen  et al.,  2005) and benign melanocytic  nevi (Michaloglou  et al.,  2005). 
Notably, OIS occurs in  benign but not in advanced tumors. This supports the view of 
OIS as important tumor-suppressive barrier. 
Dispute between studies with overexpressed mutant alleles and those with alleles 
expressed on lower levels  pointed  out  the importance  of  oncogenic  signal  intensity. 
Moreover,  this  was  later  well  demonstrated  on  MTB–TRAS mouse models.  These 
models  express  an  oncogenic  H-RAS12V allele  under  the  control  of  a  tetracycline-
inducible promoter,  which allows to titrate the levels of RAS activation. Results from 
these models showed that only high and not low levels of RAS activation were capable 
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of  senescence  induction  (Sarkisian  et  al.,  2007).  Another  problem  which  remains 
currently unclear is why some cell types are sensitive to induction of OIS, while other 
types are not.
Table 2 | Genes, whose altered expression triggers OIS
(based on Courtois-Cox et al., 2008; Di Micco et al., 2007)
Oncogenes Gene product function Cell type observed to exhibit 
senescence response
AKT
(Miyauchi et al., 2004)
kinase in Akt/PKB pathway endothelial cells
and murine embryonic fibroblasts
BRAF
(Michaloglou et al., 2005)
kinase in Raf/MEK/Erk pathway melanocytes
CDC6
(Bartkova et al., 2006)
DNA replication licensing factor human diploid fibroblasts
Cyclin E
(Bartkova et al., 2006)
CDK2 modulator U20S (cell line from 
osteosarcoma)
E2F1
(Dimri et al., 2000)
pro-growth transcription factor human diploid fibroblasts
IFN-β 
(Moiseeva et al., 2006)
cytokine human diploid fibroblasts
MEK
(Lin et al. 1998)
kinase in Raf/MEK/Erk pathway human diploid fibroblast and 
murine embryonic fibroblast 
MOS
(Bartkova et al., 2006)
activator of the Raf/MEK/Erk 
pathway
human diploid fibroblast
MYC 
(Grandori et al., 2003)
pro- growth transcription factor human diploid fibroblast
RAC1
(Debidda et al., 2006)
GTPase belonging to Ras 
superfamily of small GTP-binding 
proteins
murine embryonic fibroblast
RAF1
(Zhu et al., 1998)
protein kinase in growth-factor 
signaling pathway involved in the 
MAPK cascade.
human diploid fibroblast, murine 
embryonic fibroblast (require 
overexpression) and melanocytes
RAS
(Serrano et al., 1997)
membrane-associated small 
GTPase activating the MAPK 
cascade.
human diploid fibroblast and 
murine embryonic fibroblast 
(require overexpression)
SMURF2
(Zhang and Cohen, 2004)
SMAD specific E3 ubiquitin 
protein ligase 2
human diploid fibroblast
STAT5A
(Mallette et al., 2007)
pro- growth transcription factor human diploid fibroblasts
TGF-β
(Katakura et al., 1999)
growth-factor A549 (cell line from human lung
adenocarcinoma)
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Table 2 | Genes, whose altered expression triggers OIS
(based on Courtois-Cox et al., 2008; Di Micco et al., 2007)
Tumor suppressors Gene product function Cell type exhibiting 
senescence response
NF1
(Courtois-Cox et al., 2006)
Ras GTPase activating
protein (GAP)
human diploid fibroblasts
PML 
(Pearson et al., 2000)
regulator of p53 murine embryonic fibroblasts
PTEN
(Courtois-Cox et al., 2006)
protein or lipid phosphatase - 
inhibitor of growth factors 
signaling pathway
murine embryonic fibroblasts and 
IMR90 (human diploid fibroblast-
like cell line from lung tissue)
The whole  picture  how oncogenes  induce  senescence  has  not  yet  been  fully 
elucidated.  Several  mechanisms of OIS induction have been proposed. They are not 
mutually  exclusive  and at  least  in  some cases  they  may contribute  to  OIS together 
(Courtois-Cox et al., 2008).
4.3.3.1. Replicative stress model of OIS induction
Oncogenes  induce  the  cellular  proliferation  through  direct  or  indirect 
deregulation of cyclin-dependent kinases. In consequence, some replication origins can 
be fired repeatedly,  causing hyper-replication.  Hyper-replication  leads  to  increase in 
replicative stress, which in result generates DNA damage foci. DNA damage triggers 
DDR that can induce senescence (Figure 8).
Figure 8 | Model of OIS induction through replicative stress 
(based on model diagrams from Bartkova  et al., 2006 and Di Micco et al., 
2006)
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This  model  was  first  proposed  in  two  reports  (Bartkova  et  al.,  2005  and 
Gorgoulis et al., 2005). Gorgoulis and colleagues observed in cancer cell lines (SAOS-2 
osteosarcoma and HeLa cervical carcinoma lines) DDR, which were triggered even in 
the absence of exogenous stressor. They demonstrated that DDR is dependent on DNA 
replication. In addition,  γH2AX, 53BP1, and ATR-ATRIP complexes were detected to 
colocalize  with  replicative  stress  foci,  thus  providing  the  evidence  that  oncogene 
induced-replicative stress is capable of triggering DDR. Moreover, foci of DNA damage 
correspond with common fragile sites. Similar results were independently obtained by 
Bartkova and colleagues on U2OS cells  U2-OS cell with induced cyclin E expression. 
In  further  support  of  this  hypothesis,  inhibition  of  ATM  kinase  suppresses  the 
senescence and leads to intense tumorigenesis (Bartkova et al., 2006; Di Micco et al., 
2006). On the contrary, depletion of p16, which is also raised in response to oncogene 
activation, did not result in senescence suppression. This suggests that DDR has at least 
in the observed cases a primary role in senescence induction (Bartkova et al., 2006).
Figure 9 | Model of OIS induction via negative feedback 
signaling
Negative feedback signals are triggered by the Raf/MEK/ERK pathway. 
Hence the RAS is suppressed through suppression of Ras exchange factors, 
upregulation of Sprouty proteins and RasGAPs. In result, pro-proliferative 
signaling is ended and Rb and/or p53 pathways can be activated. 
(Adapted with slight modifications from Courtois-Cox et al., 2006).
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4.3.3.2. Alternative models of OIS induction
Lee  and  colleagues  (1999)  suggested  that  expression  of  mutant  RAS  allele 
contributes to intracellular increment of ROS. As noted above, oxidative stress is indeed 
a potent DNA damaging agent. Nevertheless, it is not certain whether the increment of 
ROS is  high  enough  to  induce  required  DDR.  Likewise,  the  mechanism by  which 
activated RAS can elevate the levels of ROS stays ill-defined and not all oncogenes 
seem  to  contribute  to  DNA  damage  through  ROS  production  (Ray  et  al.,  2006).A 
different  point of view was brought to this  issue by the report  of Courtois-Cox  and 
colleagues (2006). They proposed that the primary burst of mitogenic signaling sparks 
the negative feedback, which in result terminates the mitogenic signal and activates OIS 
(Figure 9).
4.3.4. Integrative scheme of proposed models
Figure 10 | Integrative scheme of proposed models 
The scheme demonstrates mechanisms of action of various stimuli 
that are capable of inducing cellular senescence phenotype. 
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4.4. Cellular senescence in oncogenesis and aging
4.4.1. Current view – an evolutionary trade-off
As  demonstrated  above,  cellular  senescence  plays  a  crucial  role  as  an 
oncogenesis  barrier.  Particularly  in  preneoplastic  lesions,  it  limits  further  cellular 
proliferation.  Artificially  induced  senescence  acts  also  as  an  important  outcome  of 
anticancer treatments.  Tumor-suppressive mechanisms are necessary for surviving of 
complex  multicellular  organisms.  However,  it  seems  that  they  are  not  exclusively 
beneficial and rather represent a double-edged sword.
 Senescent cells, which accumulate in tissues, no longer play a proper function 
and deplete the renewable capacity  of the tissues. In addition,  senescence-associated 
secretory  phenotype  (SAPS)  disrupts  tissue  homeostasis  through  secretion  of 
degradation  enzymes  and  cytokines  including  inflammatory  species,  which  can 
contribute  to  the  development  of  age-related  pathologies.  Indeed,  accumulation  of 
senescent  cells  has been observed at  sites  of  age-related  atherosclerosis  (Chang and 
Harley, 1995). Even more importantly, SAPS can also contribute to the development of 
cancer (Krtolica et al., 2001). This is in agreement with the observed general increase of 
cancer occurrence during aging (Meza et al., 2008). 
The contradictory effect of senescence can be explained by evolutionary theory 
of antagonistic pleiotropy (Campisi,  2003; Kirkwood and Austad, 2000). This theory 
states that pleiotropic traits, which increase survival at young age but act deleteriously 
in  old  individuals,  will  be  fixed  in  population,  because  the  benefit  in  early  life 
outweighs the deteriorative effect in old age. 
Figure 11: Evolution of aging
- deteriorate effects of pleiotropic traits were not eliminated through ages 
because of early death of our predecessors due to exogenous hazards 
(adapted from Campisi, 2003).
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Additionally,  in  natural  conditions  most  individuals  die  due  to  endogenous 
hazards  before  reaching  advanced  age  (e.g.  predation,  infections  and  starvation). 
Deteriorating  effects  of  pleiotropic  traits,  which  are  demonstrated  in  advanced  age, 
therefore end in a “shadow zone”, where natural selection cannot act. However, humans 
in developed countries get rid of nearly all natural hazards, so we can now well observe 
negative  effects  of  these  pleiotropic  traits  on ourselves,  demonstrated  as  age-related 
pathologies (Figure 11).
4.4.2. Original view – the death clock
From the very beginning of Hayflick discovery of replicative senescence, it has 
been proposed as a mechanism contributing to aging of organism. This is well reflected 
in the chosen term, the "senescence", derived from the Latin word "senescere", meaning 
"grow old". Later discovered telomere shortening was then suggested to be an intrinsic 
"death clock" - an active, teleological mechanism, which limits the renewable capacity 
of  tissues  and  thus  restrains  the  lifespan  of  complex  multicellular  organisms. 
Nevertheless, as described above, shortening of telomeres is not homogeneous, nor is 
the length of telomeres crucial for  establishment of senescence. Even if the molecular 
mechanisms of "death clock" were not disproved, the programmed aging still has to face 
several challenges. In particular, what evolutionary reason would lead to evolution of 
such a trait? 
Nusbaum (1996) suggests that aging inevitably directing to death is beneficial on 
the level of the species. According to his theory, shorter lifespan should be reflected in 
shorter duration of pregnancy, thus indirectly lead to increased number of generations in 
a time period. More frequent turnover of generations ought to result in better adaptive 
potential of the species to environmental changes. In addition, as old individuals exhaust 
the local resources, their death should enhance the living conditions of their offspring.
On the contrary, as in natural conditions extensive majority of individuals die 
young  due  to  exogenous  hazards,  why  would  there  be  a  selection  pressure  for  the 
development  of  specific  eliminating  mechanism  of  the  old  ones?  Besides,  even  if 
organisms would not die due to exogenous hazards, there would be a potent counter-
pressure against the development of aging mechanism on the levels of individuals. Non-
aging individuals would have a longer fertility span, therefore would in all probability 
leave more offspring than aging ones. This would necessarily lead to fixation of non-
aging phenotype in population, regardless of potential benefits of aging on species level.
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5. Conclusions
The field of cellular senescence has made a great leap forward in recent years. It 
has been demonstrated that DNA damage and corresponding DNA damage response 
signaling are causally linked to establishment of senescent phenotype. The model of on-
cogene-induce replicative stress proposes a plausible explanation how are activated on-
cogenes capable of cellular senescence induction. Observation of senescent cells in be-
nign and preneoplastic lesions, preventing their further  proliferation, supports a  view 
that cellular senescence acts as a tumorigenesis barrier. 
However, many questions still remain open. Numerous detailed mechanisms in 
mentioned pathways are waiting to be elucidated. Moreover, the relationship between 
parallel ways of senescence activation and significance of their impact in overall context 
are not yet fully understood.
Cellular senescence plays an  important  role in cancer and aging. Thus, it is of 
great clinical importance to further study its underlying mechanisms. Cancer is one of 
the leading causes of death in developed countries and nowadays the burden of cancer is 
constantly increasing even in many developing countries. In addition, as the aging popu-
lation grows in developed countries, it raises hand in hand the prevalence of age-related 
pathologies, which causes an increasing demand for new efficient treatments. The re-
search  of  cellular  senescence  may  hopefully  provide  requisite  knowledge  for  the 
struggle with these diseases.
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